ORGANIGRAM GLOBAL INC. (OGI) Form 6-K — May 12, 2026
Organigram Global Inc. reported a 9% decrease in net revenue to $59.8 million in Q2 Fiscal 2026, primarily due to lower recreational cannabis sales and higher product returns. The company also recognized a significant impairment loss of $5.8 million related to its U.S. hemp-derived products business, driven by new regulatory restrictions.
Key figures
- Eps Beat
- 0
- Revenue
- 59794
- Guidance
- Net revenue to exceed $350 million in Fiscal 2026, with Adjusted EBITDA and Adjusted Gross Margin exceeding Fiscal 2025 performance, Free Cash Flow approximately break even, and capital expenditures of less than $10 million.
- Total Debt
- 149500
- Debt Amount
- 60000
- Revenue Yoy
- -9
- Total Assets
- 521312
- Cash Position
- 54754
- Deal Value Usd
- 0
- Interest Rate
- 0
- Maturity Date
- April 2029
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 136468690
- Adjusted EBITDA
- 870
- Impairment Loss
- 5800
- Acquisition Cost
- 107300000
- Adjusted Gross Margin
- 18441
- International Revenue
- 6090
- Adjusted Gross Margin Percent
- 31
- Acquisition Contingent Consideration
- 113800000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.